Bioxyne (ASX:BXN), through its Breathe Life Sciences subsidiary, signed an exclusive import, manufacture, and supply agreement with Curaleaf International for the Australian market, according to a Monday filing with the Australian bourse.

Breathe Life Sciences will launch Curaleaf's Que Medical Inhalation Device (QMID) in Australia this month, upon receiving import approval notification from the Therapeutic Goods Administration and authorization from the Office of Drug Control, the filing said.

QMID is the first EU Class IIa medical device for use with medical cannabis liquid inhalants.

The deal is expected to support the company's fiscal year 2026 revenue guidance of AU$65 million to AU$75 million and earnings before interest, taxes, depreciation, and amortization guidance of AU$11.5 million to AU$13.5 million, per the filing.

Bioxyne shares fell nearly 3% in afternoon trade on Monday.